Craig S Atwood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/19246/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	3.3	12
2	Estropause, Sex Hormones and Metal Homeostasis in the Mouse Brain. Frontiers in Neurology, 2022, 13,	2.4	0
3	The roles of GnRH in the human central nervous system. Hormones and Behavior, 2022, 145, 105230.	2.1	6
4	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
5	Hypogonadism induced by surgical stress and brain trauma is reversed by human chorionic gonadotropin in male rats: A potential therapy for surgical and TBlâ€induced hypogonadism?. Endocrinology, Diabetes and Metabolism, 2021, 4, e00239.	2.4	1
6	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemporary Clinical Trials, 2021, 107, 106488.	1.8	7
7	The LUCINDA trial: Leuprolide + cholinesterase inhibition to reduce neurologic decline in Alzheimer's. Alzheimer's and Dementia, 2020, 16, e038780.	0.8	0
8	Development of Classification Models for the Prediction of Alzheimer's Disease Utilizing Circulating Sex Hormone Ratios. Journal of Alzheimer's Disease, 2020, 76, 1029-1046.	2.6	2
9	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
10	Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data. Molecular and Cellular Endocrinology, 2019, 480, 12-35.	3.2	3
11	Septal hypertrophy and cell cycle re-entry in AD. Aging, 2019, 11, 297-298.	3.1	2
12	Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data. Journal of Alzheimer's Disease, 2018, 63, 1269-1277.	2.6	4
13	Myocardial infarction in the Wisconsin Longitudinal Study: the interaction among environmental, health, social, behavioural and genetic factors. BMJ Open, 2017, 7, e011529.	1.9	6
14	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166
15	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
16	Does the degree of endocrine dyscrasia post-reproduction dictate post-reproductive lifespan? Lessons from semelparous and iteroparous species. GeroScience, 2017, 39, 103-116.	4.6	9
17	Conjugated Linoleic Acid Administration Induces Amnesia in Male Sprague Dawley Rats and Exacerbates Recovery from Functional Deficits Induced by a Controlled Cortical Impact Injury. PLoS ONE, 2017, 12, e0169494.	2.5	8
18	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. Journal of Alzheimer's Disease, 2016, 52, 1373-1383.	2.6	51

#	Article	IF	CITATIONS
19	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe Ε4 Carriers. , 2016, 12, P375-P376.		0
20	The spatiotemporal hormonal orchestration of human folliculogenesis, early embryogenesis and blastocyst implantation. Molecular and Cellular Endocrinology, 2016, 430, 33-48.	3.2	43
21	Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 1009-1019.	2.6	74
22	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. Journal of Alzheimer's Disease, 2015, 44, 549-560.	2.6	47
23	A Unified Hypothesis of Early- and Late-Onset Alzheimer's Disease Pathogenesis. Journal of Alzheimer's Disease, 2015, 47, 33-47.	2.6	45
24	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study. PLoS Medicine, 2015, 12, e1001833.	8.4	330
25	The endocrine dyscrasia that accompanies menopause and andropause induces aberrant cell cycle signaling that triggers re-entry of post-mitotic neurons into the cell cycle, neurodysfunction, neurodegeneration and cognitive disease. Hormones and Behavior, 2015, 76, 63-80.	2.1	23
26	Hypothalamic–pituitary–gonadal axis homeostasis predicts longevity. Age, 2013, 35, 129-138.	3.0	15
27	Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales. Pharmacological Reviews, 2012, 64, 1004-1026.	16.0	65
28	Lactate dyscrasia: a novel explanation for amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 569-581.	3.1	14
29	The Promises and Pitfalls of Genoeconomics. Annual Review of Economics, 2012, 4, 627-662.	5.5	168
30	Is TNF a Link between Aging-Related Reproductive Endocrine Dyscrasia and Alzheimer's Disease?. Journal of Alzheimer's Disease, 2011, 27, 691-699.	2.6	15
31	The reproductive-cell cycle theory of aging: An update. Experimental Gerontology, 2011, 46, 100-107.	2.8	50
32	The pregnancy hormones human chorionic gonadotropin and progesterone induce human embryonic stem cell proliferation and differentiation into neuroectodermal rosettes. Stem Cell Research and Therapy, 2010, 1, 28.	5.5	35
33	Differential Processing of Amyloid-β Precursor Protein Directs Human Embryonic Stem Cell Proliferation and Differentiation into Neuronal Precursor Cells. Journal of Biological Chemistry, 2009, 284, 23806-23817.	3.4	59
34	Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory proteinâ€dependent mechanism involving hypothalamicâ€pituitaryâ€gonadal axis receptors. Journal of Neurochemistry, 2009, 110, 1014-1027.	3.9	39
35	Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radical Research, 2009, 43, 156-164.	3.3	65
36	Opioid and Progesterone Signaling is Obligatory for Early Human Embryogenesis. Stem Cells and Development, 2009, 18, 737-740.	2.1	27

#	Article	IF	CITATIONS
37	Activin Receptor Signaling Regulates Prostatic Epithelial Cell Adhesion and Viability. Neoplasia, 2009, 11, 365-IN6.	5.3	25
38	A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E Îμ4 allele. BMC Medical Genetics, 2008, 9, 37.	2.1	19
39	Characterization of Copper Interactions with Alzheimer Amyloid \hat{I}^2 Peptides. Journal of Neurochemistry, 2008, 75, 1219-1233.	3.9	566
40	Redox active iron accumulation in aceruloplasminemia. Neuropathology, 2008, 28, 466-471.	1.2	46
41	fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: Risk factors for Alzheimer's disease. Neuropsychologia, 2008, 46, 1667-1678.	1.6	58
42	A multi-hit endocrine model of intrinsic adult-onset asthma. Ageing Research Reviews, 2008, 7, 114-125.	10.9	10
43	Reproductive hormones regulate the selective permeability of the blood-brain barrier. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 401-407.	3.8	85
44	A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age and Ageing, 2008, 38, 86-93.	1.6	82
45	The influence of parental history of Alzheimer's disease and apolipoprotein E Â4 on the BOLD signal during recognition memory. Brain, 2008, 132, 383-391.	7.6	79
46	Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 13, 187-197.	2.6	88
47	Gonadotropins and Cognition in Older Women. Journal of Alzheimer's Disease, 2008, 13, 267-274.	2.6	51
48	Trophoblastic hormones direct early human embryogenesis. Nature Precedings, 2008, , .	0.1	4
49	Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain. Current Alzheimer Research, 2007, 4, 67-72.	1.4	62
50	Amyloid-β precursor protein expression and modulation in human embryonic stem cells: A novel role for human chorionic gonadotropin. Biochemical and Biophysical Research Communications, 2007, 364, 522-527.	2.1	29
51	Metabolic clues regarding the enhanced performance of elite endurance athletes from orchiectomy-induced hormonal changes. Medical Hypotheses, 2007, 68, 735-749.	1.5	12
52	Leuprolide acetate: a drug of diverse clinical applications. Expert Opinion on Investigational Drugs, 2007, 16, 1851-1863.	4.1	140
53	Luteinizing hormone receptor mediates neuronal pregnenolone production via upâ€regulation of steroidogenic acute regulatory protein expression. Journal of Neurochemistry, 2007, 100, 1329-1339.	3.9	36
54	Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 447-452.	3.8	165

#	Article	IF	CITATIONS
55	Identification of a gonadotropin-releasing hormone receptor orthologue in Caenorhabditis elegans. BMC Evolutionary Biology, 2006, 6, 103.	3.2	33
56	Human neurons express type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression. Journal of Endocrinology, 2006, 191, 651-663.	2.6	64
57	Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations. Annals of the New York Academy of Sciences, 2005, 1052, 93-115.	3.8	51
58	Estrogen Bows to a New Master: The Role of Gonadotropins in Alzheimer Pathogenesis. Annals of the New York Academy of Sciences, 2005, 1052, 201-209.	3.8	43
59	The Gonadotropin Connection in Alzheimer's Disease. Endocrine, 2005, 26, 317-326.	2.2	75
60	Alzheimer?s disease: the impact of age-related changes in reproductive hormones. Cellular and Molecular Life Sciences, 2005, 62, 257-270.	5.4	144
61	What is aging? What is its role in Alzheimer's disease? What can we do about it?. Journal of Alzheimer's Disease, 2005, 7, 247-253.	2.6	21
62	Dysregulation of the Hypothalamic-Pituitary-Gonadal Axis with Menopause and Andropause Promotes Neurodegenerative Senescence. Journal of Neuropathology and Experimental Neurology, 2005, 64, 93-103.	1.7	76
63	Novel -penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 263-272.	4.3	174
64	Amyloidâ€Î²â€induced toxicity of primary neurons is dependent upon differentiationâ€associated increases in tau and cyclinâ€dependent kinase 5 expression. Journal of Neurochemistry, 2004, 88, 554-563.	3.9	77
65	Luteinizing Hormone, a Reproductive Regulator That Modulates the Processing of Amyloid-β Precursor Protein and Amyloid-β Deposition. Journal of Biological Chemistry, 2004, 279, 20539-20545.	3.4	154
66	Neuroprotective properties of Bcl-w in Alzheimer disease. Journal of Neurochemistry, 2004, 89, 1233-1240.	3.9	54
67	Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer?s A? peptides. Journal of Biological Inorganic Chemistry, 2004, 9, 954-960.	2.6	218
68	Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. Journal of Neuroscience Research, 2004, 75, 698-703.	2.9	63
69	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-β. Biochemistry, 2004, 43, 560-568.	2.5	362
70	Living and Dying for Sex. Gerontology, 2004, 50, 265-290.	2.8	126
71	The role of beta amyloid in Alzheimer?s disease: still a cause of everything or the only one who got caught?. Pharmacological Research, 2004, 50, 397-409.	7.1	153
72	Amyloid-β: phylogenesis of a chameleon. Brain Research Reviews, 2004, 46, 118-120.	9.0	15

5

#	Article	IF	CITATIONS
73	Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals, 2003, 16, 77-81.	4.1	94
74	Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radical Biology and Medicine, 2003, 34, 1070-1077.	2.9	46
75	Metal Binding and Oxidation of Amyloid-β within Isolated Senile Plaque Cores: Raman Microscopic Evidenceâ€. Biochemistry, 2003, 42, 2768-2773.	2.5	543
76	Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Research Reviews, 2003, 43, 1-16.	9.0	271
77	Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Research Reviews, 2003, 43, 164-178.	9.0	54
78	Estrogen Replacement and Risk of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 1100.	7.4	16
79	Iron: A Pathological Mediator of Alzheimer Disease?. Developmental Neuroscience, 2002, 24, 184-187.	2.0	127
80	The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders. CNS Drugs, 2002, 16, 339-352.	5.9	115
81	Predicting the failure of amyloid-Î ² vaccine. Lancet, The, 2002, 359, 1864-1865.	13.7	52
82	The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease. Peptides, 2002, 23, 1333-1341.	2.4	88
83	Senile plaque composition and posttranslational modification of amyloid-Î ² peptide and associated proteins. Peptides, 2002, 23, 1343-1350.	2.4	133
84	Amyloid-β, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?. Neurochemistry International, 2002, 40, 527-531.	3.8	70
85	Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radical Biology and Medicine, 2002, 33, 1475-1479.	2.9	266
86	Amyloid-?: A vascular sealant that protects against hemorrhage?. Journal of Neuroscience Research, 2002, 70, 356-356.	2.9	40
87	Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. Journal of Neuroscience Research, 2002, 70, 514-518.	2.9	122
88	Involvement of maillard reactions in Alzheimer disease. Neurotoxicity Research, 2002, 4, 191-209.	2.7	100
89	Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Î ² -Amyloid Accumulation in Alzheimer's Disease Transgenic Mice. Neuron, 2001, 30, 665-676.	8.1	1,419
90	The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-β Levels: Resolubilization of amyloid-β with transition metal ion chelators. Journal of Alzheimer's Disease, 2001, 3, 209-219.	2.6	44

#	Article	IF	CITATIONS
91	Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the â€~two hit' hypothesis. Mechanisms of Ageing and Development, 2001, 123, 39-46.	4.6	293
92	Redox-active iron mediates amyloid-β toxicity. Free Radical Biology and Medicine, 2001, 30, 447-450.	2.9	356
93	Active glycation in neurofibrillary pathology of Alzheimer disease: NÎμ-(Carboxymethyl) lysine and hexitol-lysine. Free Radical Biology and Medicine, 2001, 31, 175-180.	2.9	194
94	Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 759-767.	1.7	1,670
95	Biochemistry of Neurodegeneration. Science, 2001, 291, 595c-597.	12.6	13
96	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	3.6	1,179
97	Alzheimer's Disease, Î ² -Amyloid Protein and Zinc. Journal of Nutrition, 2000, 130, 1488S-1492S.	2.9	102
98	Evidence that Oxidative Challenges Promote Neuronal Sprouting and Cell Cycle Re-entry. Journal of Alzheimer's Disease, 2000, 2, 283-287.	2.6	0
99	Evidence that the β-Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of Al² by Zinc. Journal of Biological Chemistry, 2000, 275, 19439-19442.	3.4	366
100	Aqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion. Journal of Biological Chemistry, 1999, 274, 23223-23228.	3.4	454
101	The Aβ Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction. Biochemistry, 1999, 38, 7609-7616.	2.5	1,098
102	Cu(II) Potentiation of Alzheimer AÎ ² Neurotoxicity. Journal of Biological Chemistry, 1999, 274, 37111-37116.	3.4	688
103	Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis. Journal of Biological Chemistry, 1998, 273, 12817-12826.	3.4	935
104	Zinc-induced Alzheimer's Aβ1–40 Aggregation Is Mediated by Conformational Factors. Journal of Biological Chemistry, 1997, 272, 26464-26470.	3.4	287
105	Maintenance of villus height and crypt depth, and enhancement of disaccharide digestion and monosaccharide absorption, in piglets fed on cows' whole milk after weaning. British Journal of Nutrition, 1996, 76, 409-422.	2.3	215
106	Collection of fore and hind milk from the sow and the changes in milk composition during suckling. Journal of Dairy Research, 1992, 59, 287-298.	1.4	97
107	Oxidative Damage and Antioxidant Responses in Alzheimer's Disease. , 0, , 371-378.		2
108	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative		14

108 Post-translational Modification of Amyloid Deposits. , 0, , 341-361.